Vidofludimus calcium is a small molecule commercialized by Immunic, with a leading Phase III program in Relapsing Remitting Multiple Sclerosis (RRMS). According to Globaldata, it is involved in 13 clinical trials, of which 9 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vidofludimus calcium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Vidofludimus calcium is expected to reach an annual total of $864 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Vidofludimus calcium Overview

Vidofludimus calcium (IMU-838) is under development for the treatment of relapsing-remitting multiple sclerosis, progressive multiple sclerosis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primary progressive multiple sclerosis (ppms) and secondary progressive multiple sclerosis (spms). The drug candidate is administered by oral route. It is a calcium salt of vidofludimus. It targets dihydroorotate dehydrogenase (DHODH) andNurr1 (Nuclear receptor related 1). It was under development for the treatment of ulcerative colitis, primary sclerosing cholangitis and crohn's disease.

Immunic Overview

Immunic (Immunic Therapeutics) is a biopharmaceutical company that discover, develops and commercializes oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company’s pipeline products include IMU-838, a selective immune modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), other chronic inflammatory and autoimmune diseases; IMU-856, an orally small molecule modulator to treat intestinal barrier function; and IMU-935, an immunology therapy targeting ROR?t and Th17. It also evaluating therapies targeting primary sclerosing cholangitis (PSC) and guillain-barre syndrome (GBS).The company has operations in Germany, Australia and the US. Immunic Therapeutics is headquartered in New York City, New York, the US.

The operating loss of the company was US$119.5 million in FY2022, compared to an operating loss of US$91.7 million in FY2021. The net loss of the company was US$120.4 million in FY2022, compared to a net loss of US$92.9 million in FY2021.

For a complete picture of Vidofludimus calcium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.